Anlotinib (AL3818) is a novel oral multi-targeted receptor tyrosine kinase inhibitor (TKI) that targets vascular endothelial growth factor receptor (VEGFR) 1-3, c-Kit, platelet-derived growth factor receptor (PDGFR)-α/β, and fibroblast growth factor receptor (FGFR) 1–4. Anlotinib is conside...